Anthony J DeSantis1, Garrett A Enten2, Xianlong Gao1, Matthias Majetschak2. 1. Department of Surgery, University of South Florida, Tampa, FL, USA. 2. Departments of Surgery and Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL, USA.
Abstract
OBJECTIVES: Chemokine receptor antagonists are being explored for their therapeutic potential in various disease processes. As the chemokine (C-C motif) receptor 2 (CCR2) antagonist RS504393 is known to compete with ligand binding to α1-adrenoceptors, we tested a panel of 10 CCR antagonists for interactions with α1-adrenoceptors to evaluate potential cardiovascular activities and side-effect profiles. METHODS: The PRESTO-Tango β-arrestin recruitment assay was utilized to test whether the CCR antagonists interfere with α1b-AR activation upon stimulation with phenylephrine. Pressure myography with isolated rat resistance arteries was employed to assess their effects on phenylephrine-induced vasoconstriction. The following antagonists were tested: CCR1-BX471, BX513, BI639667; CCR2-RS504393, INCB3284; CCR3-SB328437; and CCR4-AZD2098, and C021; CCR5-Maraviroc; CCR10-BI6901. The pan-α1-adrenoceptor antagonist prazosin was used as control. RESULTS: Among the CCR antagonists tested, RS504393, BX513, and C021 inhibited phenylephrine-induced β-arrestin recruitment to α1b-adrenoceptor and phenylephrine-induced vasoconstriction. While RS504393 functioned as a competitive α1-adrenoceptor blocker, BX513 and C021 functioned as noncompetitive α1-adrenoceptor antagonists in both assay systems. Furthermore, RS504393, BX513, and C021 dose-dependently dilated arteries that were fully preconstricted with phenylephrine. CONCLUSIONS: Our data suggest that CCR antagonists should be screened for cross-reactivity with α1-adrenoceptors to exclude potential adverse cardiovascular effects when used as anti inflammatory drugs.
OBJECTIVES: Chemokine receptor antagonists are being explored for their therapeutic potential in various disease processes. As the chemokine (C-C motif) receptor 2 (CCR2) antagonist RS504393 is known to compete with ligand binding to α1-adrenoceptors, we tested a panel of 10 CCR antagonists for interactions with α1-adrenoceptors to evaluate potential cardiovascular activities and side-effect profiles. METHODS: The PRESTO-Tango β-arrestin recruitment assay was utilized to test whether the CCR antagonists interfere with α1b-AR activation upon stimulation with phenylephrine. Pressure myography with isolated rat resistance arteries was employed to assess their effects on phenylephrine-induced vasoconstriction. The following antagonists were tested: CCR1-BX471, BX513, BI639667; CCR2-RS504393, INCB3284; CCR3-SB328437; and CCR4-AZD2098, and C021; CCR5-Maraviroc; CCR10-BI6901. The pan-α1-adrenoceptor antagonist prazosin was used as control. RESULTS: Among the CCR antagonists tested, RS504393, BX513, and C021 inhibited phenylephrine-induced β-arrestin recruitment to α1b-adrenoceptor and phenylephrine-induced vasoconstriction. While RS504393 functioned as a competitive α1-adrenoceptor blocker, BX513 and C021 functioned as noncompetitive α1-adrenoceptor antagonists in both assay systems. Furthermore, RS504393, BX513, and C021 dose-dependently dilated arteries that were fully preconstricted with phenylephrine. CONCLUSIONS: Our data suggest that CCR antagonists should be screened for cross-reactivity with α1-adrenoceptors to exclude potential adverse cardiovascular effects when used as anti inflammatory drugs.
Authors: T Mirzadegan; F Diehl; B Ebi; S Bhakta; I Polsky; D McCarley; M Mulkins; G S Weatherhead; J M Lapierre; J Dankwardt; D Morgans; R Wilhelm; K Jarnagin Journal: J Biol Chem Date: 2000-08-18 Impact factor: 5.157
Authors: Abhishek Tripathi; P Geoff Vana; Tanmay S Chavan; Lioubov I Brueggemann; Kenneth L Byron; Nadya I Tarasova; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak Journal: Proc Natl Acad Sci U S A Date: 2015-03-16 Impact factor: 11.205
Authors: Harold H Bach; Yee M Wong; Abhishek Tripathi; Amanda M Nevins; Richard L Gamelli; Brian F Volkman; Kenneth L Byron; Matthias Majetschak Journal: Mol Med Date: 2014-10-13 Impact factor: 6.354
Authors: Wesley K Kroeze; Maria F Sassano; Xi-Ping Huang; Katherine Lansu; John D McCorvy; Patrick M Giguère; Noah Sciaky; Bryan L Roth Journal: Nat Struct Mol Biol Date: 2015-04-20 Impact factor: 15.369
Authors: Lauren J Albee; Heather M LaPorte; Xianlong Gao; Jonathan M Eby; You-Hong Cheng; Amanda M Nevins; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak Journal: Open Biol Date: 2018-01 Impact factor: 6.411